CASP3 and hepatocellular carcinoma: KCC-NH2-FA-CR can activate caspase-3 as the main route for apoptosis; therefore, KCC-NH2-FA-CR is a promising therapeutic nano-agent target for human HCC treatments with a selective anticancer mechanism.